A phase I, randomized, observer- and subject-blind, placebo-controlled, single ascending dose study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of GSK1827771 in healthy volunteers.

Trial Profile

A phase I, randomized, observer- and subject-blind, placebo-controlled, single ascending dose study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of GSK1827771 in healthy volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs GSK 1827771 (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Biomarker
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 23 Jan 2012 Actual initiation date changed from (1 Oct 2007) to (1 Sep 2007) as reported by ClinicalTrials.gov.
    • 12 Jun 2008 Actual study completion date (Apr 2008) added as reported by ClinicalTrials.gov.
    • 12 Jun 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top